Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 8/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 8/20 | 0.52 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.52 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743574 | 0.81 | CCR4 (0.44) | KCNQ3KCNQ2KCNQ4KCNQ5MAP4K4 | |
| SCHEMBL322079 | 0.77 | KCNQ3 (0.50) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL5765855 | 0.76 | MAPK1 (0.50) | KCNQ3KCNQ2 | |
| SCHEMBL4609021 | 0.75 | MAP4K4 (0.41) | KCNQ3KCNQ2MAP4K4 | |
| SCHEMBL21500109 | 0.72 | MAP4K4 (0.55) | KCNQ3KCNQ2KCNQ4KCNQ5MAP4K4 | |
| SCHEMBL11696330 | 0.71 | HTT (0.53) | KCNQ3KCNQ2HTR2C | |
| SCHEMBL23578988 | 0.70 | SCD (0.44) | KCNQ3KCNQ2KCNQ4KCNQ5MAP4K4 | |
| SCHEMBL15740461 | 0.70 | EGFR (0.49) | MAP4K4 | |
| SCHEMBL29722778 | 0.70 | EGFR (0.49) | MAP4K4 | |
| SCHEMBL29959132 | 0.70 | SCD (0.44) | KCNQ3KCNQ2KCNQ4KCNQ5MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883812-B2 | Piperidinyl pyrimidine amides as Kv7 potassium channel openers | PFIZER INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2590961-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | Pfizer Inc (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004698-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | PFIZER INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | KCNA7, KCNK17, KCNQ5 | KCNQ3 6/4885KCNQ2 4/4885KCNQ4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.